BIOCYTOGEN
15.9.2022 14:03:42 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation to Exhibit Advanced Warehouse Automation Solutions at LogiMAT 20264.3.2026 09:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, will exhibit its latest advancements in warehouse automation at LogiMAT 2026. The world’s largest trade show for intralogistics solutions and process management, LogiMAT will be held March 24 through 26 at the Stuttgart Trade Fair Center in Germany. “Our team looks forward to being onsite at LogiMAT and showcasing several of our leading warehouse automation solutions,” said Alex Stevens, President, Warehouse Automation, OPEX. “We’re proud to deliver cutting-edge systems that help our clients transform how they conduct business, and we appreciate the vast opportunity LogiMAT provides to share our offerings and expertise with event attendees.” At LogiMAT Hall 5 ‒ Stand B25, OPEX will demonstrate Sure Sort® X with Xtract, its award-winning, automated pack-out and order takeaway system. The OPEX Booth will also feature a static display of the company’
Twilio and KPN Partnership Unlocks the Next Generation of Secure Business Messaging in the Netherlands, Powered by Google4.3.2026 09:00:00 CET | Press release
Milestone marks nationwide operator support for RCS Business Messaging, opening a scalable new market for brands Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalised experiences for today’s leading brands, today announced at Mobile World Congress a partnership with KPN Netherlands (KPN) to enable nationwide Rich Communication Services (RCS) Business Messaging across all major mobile operators in the Netherlands, powered by Twilio and Google. RCS Business Messaging combines the simplicity and reach of sms with rich, interactive features such as verified sender identity, images, carousels and action buttons. This allows businesses to communicate in a more engaging, secure and measurable way, strengthening customer trust and improving the overall experience. Enabling nationwide RCS in the Netherlands With nation-wide coverage, KPN plays a central role in the country’s digital infrastructure. By joining the growing RCS ecosystem, this marks a defining m
SES Brings Satellite Connectivity to Refugees in Chad4.3.2026 08:50:00 CET | Press release
First Medium-Earth Orbit (MEO) deployment of the emergency.lu platform for refugees and their host communities’ use provides dependable broadband for humanitarian responders, classrooms and community connectivity centers SES, a space solutions company, is expanding humanitarian connectivity at the Farchana refugee settlement in Chad in cooperation with emergency.lu, the public-private partnership led by Luxembourg’s Ministry of Foreign and European Affairs, Defence, Development Cooperation and Foreign Trade and the UN Refugee Agency. In the framework of the Connectivity for Refugees initiative, the deployment uses SES’ O3b mPOWER satellite network to provide dependable, high-speed internet for humanitarian teams and essential services for refugees. This is the first emergency.lu deployment using O3b mPOWER satellites in Medium Earth Orbit (MEO), an expansion beyond the program’s previous use of geostationary (GEO) satellites for rapid disaster-response missions. It also marks a new app
Travel Smarter: Thales and Airalo Unlock a Seamless Global eSIM Experience4.3.2026 08:00:00 CET | Press release
Powered by Thales’ secure technology in eSIM connectivity management, this new solution ensures fast connection to local networks worldwide, delivering a smoother, more intuitive eSIM experience. For travellers, this means a simple eSIM installation for a seamless experience across 200+ destinations, making global connectivity as effortless and accessible as booking a flight or hotel. International travellers have increasingly relied on travel eSIMs to avoid high roaming fees, the hassle of searching for a local SIM card or relying on Wi-Fi hotspots. While this has improved connectivity access for millions, the process in the travel space remains cumbersome, still requiring manual configuration for each trip. By integrating Thales’ eSIM capabilities into its global platform, Airalo, the world’s largest travel eSIM platform, is further enhancing its technical architecture to provide its over 20 million users with a smoother travel experience. This press release features multimedia. View
Kao’s Laurier Launches New Brand Communication Initiative across Asia: Strengthening Global Integration as a Core Brand in Kao’s Asian Business4.3.2026 03:10:00 CET | Press release
Starting on International Women’s Day, March 8, Kao Corporation (TOKYO:4452) will launch new brand communication campaign in nine Asian countries and regions for its feminine sanitary product brand, Laurier, which is the core of its Asian business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303996141/en/ Laurier Campaign Key Visual Laurier aims to help create more supportive and understanding environments around menstruation, so that women can feel more at ease, both physically and emotionally, under the key message “Comfort, Made Together,” which will be implemented simultaneously across Asia. Kao aims to further develop Laurier as a global brand. Laurier, one of the core brands supporting Kao’s consumer care business in Asia, has been promoting globally integrated operations since 2023. Across all nine Asian countries and regions including Japan, Laurier has been working to unify product specifications and consolida
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom